Related Experiment Video
Updated: Jun 9, 2025
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Combination Antitumor Activation of Anlotinib with Radiofrequency Ablation in Human Medullary Thyroid Carcinoma
Zhou Zhao1,2, Xue Ma3, Yuanmeng Li1
1Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Introduction:
Currently, Medullary Thyroid Carcinoma (MTC) is considered a kind of rare neuroendocrine tumor, and molecular-targeted drugs have previously been used for MTC treatment. However, the prognosis of MTC patients is still unsatisfactory. In the present work, we aimed to explore the antitumor activity of the molecularly targeted drug anlotinib in combination with radiofrequency ablation on MTC.
Methods:
44 MTC clinical specimens were involved. The targets of anlotinib in malignant cells were examined by qPCR. We cultured MTC cells line TT and treated with a series of concentration of TKIs. Then measure the inhibitory rates of TT cell survival. We established a subcutaneous tumorigenic model in nude mice to examine the antitumor effects of anlotinib combined with different RFA conditions.
Results:
The targets of anlotinib were clearly expressed in MTC tissue specimens, and the expression level of these factors was much higher in MTC clinical specimens than in nontumor tissues. At the same time, anlotinib or Radiofrequency Ablation (RFA) showed clear antitumor activity against the MTC cell line TT (TT cells) and the tumor tissue it formed.
Conclusion:
These results indicated that the combination of anlotinib with RFA could be a promising therapeutic strategy for MTC treatment.
Insights
Combining anlotinib with radiofrequency ablation (RFA) shows significant promise for treating Medullary Thyroid Carcinoma (MTC). This novel therapeutic strategy enhances RFA
Area of Science:
- Oncology
- Molecular Biology
- Medical Physics
Background:
- Medullary Thyroid Carcinoma (MTC) is a rare neuroendocrine tumor with limited treatment options.
- Current molecular-targeted drugs offer some benefit, but patient prognosis remains suboptimal.
- Anlotinib targets are overexpressed in MTC tissues, suggesting potential therapeutic value.
Purpose of the Study:
- To investigate the combined antitumor activity of anlotinib and radiofrequency ablation (RFA) in Medullary Thyroid Carcinoma (MTC).
- To evaluate the efficacy of this combination therapy for MTC treatment.
Main Methods:
- Assessment of anlotinib target expression in MTC clinical specimens.
- In vitro and in vivo evaluation of anlotinib and RFA monotherapy.
- Analysis of the combined antitumor effects of anlotinib and RFA on MTC.
Main Results:
- Anlotinib targets showed significantly higher expression in MTC tissues compared to non-tumor tissues.
- Both anlotinib and RFA demonstrated antitumor activity against MTC cell lines and tumors.
- The combination of anlotinib with RFA significantly enhanced the antitumor efficacy of RFA.
Conclusions:
- The combination of anlotinib and RFA presents a promising therapeutic strategy for Medullary Thyroid Carcinoma.
- This combined approach offers enhanced antitumor activity, potentially improving patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy